Trademark Overview
On Thursday, September 4, 2025, a trademark application was filed for BELHIRVI with the United States Patent and Trademark Office. The USPTO has given the BELHIRVI trademark a serial number of 99374629. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, January 16, 2026. This trademark is owned by Glaxo Group Limited. The BELHIRVI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives